Apellis Pharmaceuticals, Inc. filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company with common stock registered under the Exchange Act. The company’s 8-K reports cover product revenue disclosures for SYFOVRE and EMPAVELI, cash and financial-condition updates, and material agreements related to collaborations, royalty arrangements, financing consents, and strategic transaction activity.
Apellis filings also record governance and compensation matters, including board appointments, director compensation, executive separation and retention plans, and related equity-award provisions. These documents disclose formal corporate actions, capital-structure references, material-event reporting, and the company’s public-company obligations as a Delaware issuer.
Deep Track Capital, Deep Track Biotechnology Master Fund, Ltd., and David Kroin filed an amended Schedule 13G/A reporting beneficial ownership of 4,532,374 shares of Apellis Pharmaceuticals common stock, representing 3.55% of the class. The filing states shared voting and dispositive power over those shares and references 127,829,909 shares outstanding as of February 17, 2026. The signatures are dated May 15, 2026.
Apellis Pharmaceuticals, Inc. reports beneficial ownership disclosure by RTW Investments, LP and Roderick Wong. The filing states each Reporting Person holds 3,685,045 shares, representing 2.9% of Common Stock based on 127,829,909 Shares outstanding as of February 17, 2026. The shares are reported as subject to shared voting and dispositive power held by RTW Investments and Dr. Wong.
Apellis Pharmaceuticals director Dunlop A. Sinclair reported disposing of all reported equity interests in connection with the company’s merger with Biogen. Common shares tendered before the offer’s expiration were exchanged for $41.00 in cash per share plus one contingent value right (CVR) per share, with potential additional payments of up to an aggregate $4.00 in cash per share upon specified milestones. Additional common stock entries reflect dispositions to the issuer and through the tender offer, leaving no shares reported as held afterward. Vested stock options with exercise prices below $41.00 were cancelled and converted into the right to receive cash based on the spread to $41.00 plus one CVR per underlying share, while options with exercise prices at or above $45.00 were cancelled without consideration.
Apellis Pharmaceuticals VP and Chief Accounting Officer James George Chopas reported multiple equity changes tied to the company’s acquisition by Biogen. On May 14, 2026, he tendered 65,955 shares of common stock in a tender offer, receiving $41.00 in cash per share plus one contingent value right (CVR) that can pay up to an additional $4.00 per share upon specified milestones.
In connection with the same merger, his outstanding stock options and restricted stock unit (RSU) awards were either cancelled for no value if deeply out of the money, or converted into rights to cash payments based on the $41.00 cash amount and corresponding CVRs. The filing shows several compensation-related grants of common stock and RSU‑linked awards on the same date and paired dispositions back to the issuer under the merger terms. After these transactions, Chopas holds no remaining direct common stock or stock options in Apellis, which is now a wholly owned subsidiary of Biogen.
Apellis Pharmaceuticals director Mikael Dolsten reported dispositions tied to the company’s acquisition by Biogen. He disposed of 14,312 shares of common stock and 24,135 stock options in connection with a tender offer and subsequent merger. Each common share was exchanged for $41.00 in cash plus one contingent value right (CVR), with potential additional cash payments of up to $4.00 per share if specified milestones are achieved. Vested options with exercise prices below $41.00 were cancelled and converted into cash equal to $41.00 minus the exercise price per option share, plus one CVR per underlying share. Following these transactions, Dolsten reported no remaining direct holdings or options in Apellis.
Apellis Pharmaceuticals chief research and development officer Leslie Meltzer reported equity transactions tied to the closing of the company’s merger with Biogen. Common shares tendered before the offer expiration were exchanged for $41.00 in cash per share plus one contingent value right (CVR) that may pay up to an additional $4.00 in cash per share upon specified milestones. The filing shows 107,024 shares of common stock disposed of pursuant to the tender offer and 92,592 stock options with a $27.93 exercise price cancelled in exchange for cash and CVRs. Restricted stock units were converted into rights to future cash and CVR payments that continue to vest over time, including performance-based awards certified at 200% of target after relative total shareholder return reached the 93.3rd percentile. Following these transactions, the report shows no remaining common stock or options held directly.
Apellis Pharmaceuticals director Paul R. Fonteyne reported disposing of his equity interests in connection with Biogen’s acquisition of Apellis. On the Form 4 date, multiple blocks of Apellis common stock were either surrendered to the issuer or delivered into a tender offer.
Under the merger agreement among Apellis, Biogen and a Biogen subsidiary, each tendered share of Apellis common stock was exchanged for $41.00 in cash per share plus one contractual, non-transferable contingent value right, or CVR, per share. Each CVR can pay up to an additional $4.00 in cash if specified milestones are met.
In addition, vested or transaction-vested stock options with exercise prices below $41.00 were cancelled and converted into cash payments equal to the spread over $41.00, plus one CVR per underlying share, while higher-priced options at or above $45.00 per share were cancelled without consideration. Following these transactions, the positions reported in this Form 4 show zero shares remaining.
Apellis Pharmaceuticals’ Chief Financial Officer Timothy Sullivan reported multiple equity award changes tied to the company’s acquisition by Biogen. Common shares tendered before the offer’s expiration were exchanged for $41.00 in cash per share plus one contractual contingent value right (CVR) per share.
Each CVR can pay up to an aggregate $4.00 in cash if specified milestones are achieved. After completion of the tender offer, Biogen’s subsidiary merged into Apellis, making Apellis a wholly owned subsidiary. Outstanding common stock was automatically converted into the right to receive the cash-and-CVR offer price.
Restricted stock units were cancelled and converted into cash-and-CVR rights that continue to vest over time, with performance conditions removed. Vested and certain unvested stock options were cancelled and converted into cash and/or CVRs depending on exercise price, while options with exercise prices at or above $45.00 were cancelled without consideration.
Apellis Pharmaceuticals director Alec Machiels reported multiple disposals of Apellis common stock tied to Biogen’s acquisition of the company. On May 14, 2026, shares tendered in the offer were exchanged for $41.00 in cash per share plus one contingent value right (CVR) that may pay up to an additional $4.00 per share upon specified milestones. Dispositions included 384,989 directly held shares and indirect holdings such as 250,000 shares held by Bauhaus 1 LLC and 150,000 shares in a spouse trust. Following these actions and the cancellation of various stock options, the filing shows Machiels with no remaining Apellis equity, as Apellis became a wholly owned subsidiary of Biogen.
Apellis Pharmaceuticals’ Chief Scientific Officer Pascal Deschatelets reported multiple equity transactions tied to the closing of Biogen’s acquisition of the company. On the completion of Biogen’s tender offer and merger, 1,177,222 common shares were disposed of into the offer.
Each tendered share was exchanged for $41.00 in cash plus one contingent value right (CVR) with potential additional cash payments of up to an aggregate $4.00 per share upon specified milestones. Outstanding RSUs and stock options were cancelled or converted into cash-and-CVR rights based on their vesting terms and exercise prices, while certain underwater options were cancelled without consideration.